Skip to content
DataLookout
Menu

NCT07253142

A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 29, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 10
    • Start date changed from estimate of Jan 14, 2026 to Feb 5, 2026
    v3
  3. Notable Eligibility criteria expanded, about 24 wordsv2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

ORR
Timeframe: up to 24 week

Secondary (4)

PFS
ORR
OS
Incidence and severity of adverse events (AEs)

Arms and interventions

HLX43 dose 1Experimental

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first).

HLX43 dose 2Experimental

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), Until disease progression, initiation of a new anti-tumor therapy, death, emergence of intolerable toxicity, or withdrawal of informed consent (whichever occurs first)

Drugs: HLX43 dose 1, HLX43 dose 2

Sites

10 sites in 1 country